Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis

Background: Inflammation and fibrosis are typical symptoms of non-alcoholic steatohepatitis (NASH), which is one of the most common chronic liver diseases. The cGAS-STING signaling pathway has been implicated in the progression of NASH, and targeting this pathway may represent a new therapeutic stra...

Full description

Saved in:
Bibliographic Details
Main Authors: Wei Luo (Author), Guang Xu (Author), Zheng Song (Author), Wenqing Mu (Author), Jincai Wen (Author), Siwen Hui (Author), Jia Zhao (Author), Xiaoyan Zhan (Author), Zhaofang Bai (Author), Xiaohe Xiao (Author)
Format: Book
Published: Frontiers Media S.A., 2023-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_38e9d43dcb6d4d0889faa1e4e221ee9f
042 |a dc 
100 1 0 |a Wei Luo  |e author 
700 1 0 |a Wei Luo  |e author 
700 1 0 |a Wei Luo  |e author 
700 1 0 |a Guang Xu  |e author 
700 1 0 |a Guang Xu  |e author 
700 1 0 |a Guang Xu  |e author 
700 1 0 |a Zheng Song  |e author 
700 1 0 |a Zheng Song  |e author 
700 1 0 |a Wenqing Mu  |e author 
700 1 0 |a Wenqing Mu  |e author 
700 1 0 |a Wenqing Mu  |e author 
700 1 0 |a Jincai Wen  |e author 
700 1 0 |a Jincai Wen  |e author 
700 1 0 |a Siwen Hui  |e author 
700 1 0 |a Siwen Hui  |e author 
700 1 0 |a Jia Zhao  |e author 
700 1 0 |a Jia Zhao  |e author 
700 1 0 |a Jia Zhao  |e author 
700 1 0 |a Xiaoyan Zhan  |e author 
700 1 0 |a Xiaoyan Zhan  |e author 
700 1 0 |a Zhaofang Bai  |e author 
700 1 0 |a Zhaofang Bai  |e author 
700 1 0 |a Xiaohe Xiao  |e author 
700 1 0 |a Xiaohe Xiao  |e author 
700 1 0 |a Xiaohe Xiao  |e author 
245 0 0 |a Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis 
260 |b Frontiers Media S.A.,   |c 2023-04-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2023.1160445 
520 |a Background: Inflammation and fibrosis are typical symptoms of non-alcoholic steatohepatitis (NASH), which is one of the most common chronic liver diseases. The cGAS-STING signaling pathway has been implicated in the progression of NASH, and targeting this pathway may represent a new therapeutic strategy. Licorice is a widely used herb with anti-inflammatory and liver-protective properties. In this study, we assessed the effect of licorice extract on the cGAS-STING pathway.Methods: Bone marrow-derived macrophages (BMDMs) were treated with licorice extract and then stimulated with HT-DNA, 2'3'-cGAMP, or other agonists to activate the cGAS-STING pathway. Quantitative real-time PCR and western blot were conducted to analyze whether licorice extract could affect the cGAS-STING pathway. Methionine and choline-deficient diet (MCD) was used to induce NASH in mice, which were treated with licorice extract (500 mg/kg) by gavage and/or c-176 (15 mg/kg) by intraperitoneal injection every 2 days. After 6 weeks of treatment, histological analysis of liver tissue was performed, along with measurements of plasma biochemical parameters.Results: Licorice extract inhibits cGAS-STING pathway activation. Mechanistically, it might function by inhibiting the oligomerization of STING. Treatment with licorice extract reduced inflammation and fibrosis in MCD diet-induced NASH mice models. Furthermore, we found that the therapeutic effect of combination treatment with licorice extract and C-176 (STING inhibitor) on the pathology and fibrosis of MCD diet-induced NASH models was similar to that of licorice extract or C-176 administered alone.Conclusion: Licorice extract can inhibit the cGAS-STING pathway and improve hepatic inflammation and fibrosis in NASH mice models. It strongly suggests that licorice extract may be a candidate therapeutic for NASH. 
546 |a EN 
690 |a licorice extract 
690 |a non-alcoholic steatohepatitis 
690 |a anti-fibrosis 
690 |a anti-inflammatory 
690 |a cGAS-STING 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 14 (2023) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2023.1160445/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/38e9d43dcb6d4d0889faa1e4e221ee9f  |z Connect to this object online.